Author Details :
Volume : 6, Issue : 4, Year : 2020
Article Page : 243-247
Aim: A prospective, randomised and comparative study to compare the efficacy and complications of triamcinolone acetonide (TMA)40mg/ml with TMA 10mg/ml in treatment of Chalazion.
Material and Methods: Sixty chalazion patients were randomly grouped into two groups. Group A patients received single intralesional injection of 0.2ml TMA 40mg/ml and group B 0.2ml of TMA 10mg/ml. The outcome and complications are evaluated at the end of 6 weeks.
Results: There were 60 chalazion from 58 patients, two patients with bilateral chalazion. There were 28 chalazion in group A and 32 chalazion in group B.Over all cure rate was 68.3% (41/60) and comparable to earlier study (P=0.70). The success rate of 78.6%(22/28) in group A is significantly more than the success rate of 56.3%(18/32) in group B (P=0.05). The cumulative complications are marginally more in group A 14.3 % (4/28) (7.2% with raised intraocular pressure (IOP) of>15 mmHg and 7.2% with cosmetically blemish yellow white deposit in skin) compare to 6.3% (2/32) in group B (cosmetically blemish yellow white deposit in skin) (P=0.41).
Conclusion: Single dose of intralesional injection of higher concentration of TMA 40mg/ml is more effective than TMA 10mg/ml. However vision threatening complication of raised IOP and Aesthetical dissatisfaction due to yellow white deposit in the lid skin are the disadvantages. Glaucoma comprehensive eye examination and repeated counseling sessions in cosmetically anxious young female patients to be kept in mind.
Keywords: Chalazion intralesional injection, TMA, Yellow deposit.
How to cite : Naik V N, Vasu S B, Comparison of intralesional injection of triamcinolone - 40 mg/ml and Triamcinolone -10 mg/ml in treatment of chalazion. IP Int J Ocul Oncol Oculoplasty 2020;6(4):243-247
Copyright © 2020 by author(s) and IP Int J Ocul Oncol Oculoplasty. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)